Oral anticoagulation may prolong survival of a subgroup of patients with cancer: A cochrane systematic review

Elie A. Akl, G. Kamath, S. Y. Kim, V. Yosuico, M. Barba, I. Terrenato, F. Sperati, H. J. Schünemann

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

To evaluate the effectiveness and safety of oral anticoagulants in improving survival of cancer patients. We conducted in January 2007 a comprehensive search for relevant randomized clinical trials (RCTs). We extracted data on methodological quality, participants, interventions and outcomes using a standardized form. Five RCTs fulfilled the inclusion criteria and all compared warfarin to either placebo or no intervention. Their overall methodological quality was acceptable. The effect of warfarin on mortality was not statistically significant at 6 months (RR=0.96; 95% CI 0.80-1.16), at 1 year (RR=0.95; 95% CI 0.86-1.05), at 2 years (RR=0.97; 95% CI 0.87-1.08) or at 5 years (RR 0.91; 95% CI 0.83-1.01). In the subgroup of patients with small cell lung cancer (SCLC), warfarin reduced mortality at 6 months (RR=0.69; 95% CI 0.50-0.96) but not at 1 year (RR=0.88; 95% CI 0.77-1.01). This 6 months mortality benefit was statistically significant in the subgroup of extensive SCLC (RR=0.65; 95% CI 0.45-0.93) but not in the subgroup of limited SCLC (RR=0.68; 95% CI 0.36-1.28). Warfarin increased both major bleeding (RR=4.24; 95% CI 1.85-9.68) and minor bleeding (RR=3.34; 95% CI 1.66-6.74). The evidence suggests a survival benefit from warfarin in patients with extensive SCLC, but not in other patient groups. This survival benefit should be weighed against the increased risk for hemorrhage.

Original languageEnglish
Pages (from-to)175-184
Number of pages10
JournalJournal of Experimental and Clinical Cancer Research
Volume26
Issue number2
Publication statusPublished - Jun 2007

Fingerprint

Warfarin
Small Cell Lung Carcinoma
Survival
Neoplasms
Hemorrhage
Mortality
Randomized Controlled Trials
Anticoagulants
Placebos
Safety

Keywords

  • Cancer
  • Coumadin
  • Oral anticoagulant
  • Vitamin K antagonist
  • Warfarin
  • Ximelagatran

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Akl, E. A., Kamath, G., Kim, S. Y., Yosuico, V., Barba, M., Terrenato, I., ... Schünemann, H. J. (2007). Oral anticoagulation may prolong survival of a subgroup of patients with cancer: A cochrane systematic review. Journal of Experimental and Clinical Cancer Research, 26(2), 175-184.

Oral anticoagulation may prolong survival of a subgroup of patients with cancer : A cochrane systematic review. / Akl, Elie A.; Kamath, G.; Kim, S. Y.; Yosuico, V.; Barba, M.; Terrenato, I.; Sperati, F.; Schünemann, H. J.

In: Journal of Experimental and Clinical Cancer Research, Vol. 26, No. 2, 06.2007, p. 175-184.

Research output: Contribution to journalArticle

Akl, EA, Kamath, G, Kim, SY, Yosuico, V, Barba, M, Terrenato, I, Sperati, F & Schünemann, HJ 2007, 'Oral anticoagulation may prolong survival of a subgroup of patients with cancer: A cochrane systematic review', Journal of Experimental and Clinical Cancer Research, vol. 26, no. 2, pp. 175-184.
Akl, Elie A. ; Kamath, G. ; Kim, S. Y. ; Yosuico, V. ; Barba, M. ; Terrenato, I. ; Sperati, F. ; Schünemann, H. J. / Oral anticoagulation may prolong survival of a subgroup of patients with cancer : A cochrane systematic review. In: Journal of Experimental and Clinical Cancer Research. 2007 ; Vol. 26, No. 2. pp. 175-184.
@article{8b9aad9b51aa424593f87d0241516b3b,
title = "Oral anticoagulation may prolong survival of a subgroup of patients with cancer: A cochrane systematic review",
abstract = "To evaluate the effectiveness and safety of oral anticoagulants in improving survival of cancer patients. We conducted in January 2007 a comprehensive search for relevant randomized clinical trials (RCTs). We extracted data on methodological quality, participants, interventions and outcomes using a standardized form. Five RCTs fulfilled the inclusion criteria and all compared warfarin to either placebo or no intervention. Their overall methodological quality was acceptable. The effect of warfarin on mortality was not statistically significant at 6 months (RR=0.96; 95{\%} CI 0.80-1.16), at 1 year (RR=0.95; 95{\%} CI 0.86-1.05), at 2 years (RR=0.97; 95{\%} CI 0.87-1.08) or at 5 years (RR 0.91; 95{\%} CI 0.83-1.01). In the subgroup of patients with small cell lung cancer (SCLC), warfarin reduced mortality at 6 months (RR=0.69; 95{\%} CI 0.50-0.96) but not at 1 year (RR=0.88; 95{\%} CI 0.77-1.01). This 6 months mortality benefit was statistically significant in the subgroup of extensive SCLC (RR=0.65; 95{\%} CI 0.45-0.93) but not in the subgroup of limited SCLC (RR=0.68; 95{\%} CI 0.36-1.28). Warfarin increased both major bleeding (RR=4.24; 95{\%} CI 1.85-9.68) and minor bleeding (RR=3.34; 95{\%} CI 1.66-6.74). The evidence suggests a survival benefit from warfarin in patients with extensive SCLC, but not in other patient groups. This survival benefit should be weighed against the increased risk for hemorrhage.",
keywords = "Cancer, Coumadin, Oral anticoagulant, Vitamin K antagonist, Warfarin, Ximelagatran",
author = "Akl, {Elie A.} and G. Kamath and Kim, {S. Y.} and V. Yosuico and M. Barba and I. Terrenato and F. Sperati and Sch{\"u}nemann, {H. J.}",
year = "2007",
month = "6",
language = "English",
volume = "26",
pages = "175--184",
journal = "Journal of Experimental and Clinical Cancer Research",
issn = "0392-9078",
publisher = "BioMed Central Ltd.",
number = "2",

}

TY - JOUR

T1 - Oral anticoagulation may prolong survival of a subgroup of patients with cancer

T2 - A cochrane systematic review

AU - Akl, Elie A.

AU - Kamath, G.

AU - Kim, S. Y.

AU - Yosuico, V.

AU - Barba, M.

AU - Terrenato, I.

AU - Sperati, F.

AU - Schünemann, H. J.

PY - 2007/6

Y1 - 2007/6

N2 - To evaluate the effectiveness and safety of oral anticoagulants in improving survival of cancer patients. We conducted in January 2007 a comprehensive search for relevant randomized clinical trials (RCTs). We extracted data on methodological quality, participants, interventions and outcomes using a standardized form. Five RCTs fulfilled the inclusion criteria and all compared warfarin to either placebo or no intervention. Their overall methodological quality was acceptable. The effect of warfarin on mortality was not statistically significant at 6 months (RR=0.96; 95% CI 0.80-1.16), at 1 year (RR=0.95; 95% CI 0.86-1.05), at 2 years (RR=0.97; 95% CI 0.87-1.08) or at 5 years (RR 0.91; 95% CI 0.83-1.01). In the subgroup of patients with small cell lung cancer (SCLC), warfarin reduced mortality at 6 months (RR=0.69; 95% CI 0.50-0.96) but not at 1 year (RR=0.88; 95% CI 0.77-1.01). This 6 months mortality benefit was statistically significant in the subgroup of extensive SCLC (RR=0.65; 95% CI 0.45-0.93) but not in the subgroup of limited SCLC (RR=0.68; 95% CI 0.36-1.28). Warfarin increased both major bleeding (RR=4.24; 95% CI 1.85-9.68) and minor bleeding (RR=3.34; 95% CI 1.66-6.74). The evidence suggests a survival benefit from warfarin in patients with extensive SCLC, but not in other patient groups. This survival benefit should be weighed against the increased risk for hemorrhage.

AB - To evaluate the effectiveness and safety of oral anticoagulants in improving survival of cancer patients. We conducted in January 2007 a comprehensive search for relevant randomized clinical trials (RCTs). We extracted data on methodological quality, participants, interventions and outcomes using a standardized form. Five RCTs fulfilled the inclusion criteria and all compared warfarin to either placebo or no intervention. Their overall methodological quality was acceptable. The effect of warfarin on mortality was not statistically significant at 6 months (RR=0.96; 95% CI 0.80-1.16), at 1 year (RR=0.95; 95% CI 0.86-1.05), at 2 years (RR=0.97; 95% CI 0.87-1.08) or at 5 years (RR 0.91; 95% CI 0.83-1.01). In the subgroup of patients with small cell lung cancer (SCLC), warfarin reduced mortality at 6 months (RR=0.69; 95% CI 0.50-0.96) but not at 1 year (RR=0.88; 95% CI 0.77-1.01). This 6 months mortality benefit was statistically significant in the subgroup of extensive SCLC (RR=0.65; 95% CI 0.45-0.93) but not in the subgroup of limited SCLC (RR=0.68; 95% CI 0.36-1.28). Warfarin increased both major bleeding (RR=4.24; 95% CI 1.85-9.68) and minor bleeding (RR=3.34; 95% CI 1.66-6.74). The evidence suggests a survival benefit from warfarin in patients with extensive SCLC, but not in other patient groups. This survival benefit should be weighed against the increased risk for hemorrhage.

KW - Cancer

KW - Coumadin

KW - Oral anticoagulant

KW - Vitamin K antagonist

KW - Warfarin

KW - Ximelagatran

UR - http://www.scopus.com/inward/record.url?scp=34347406492&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34347406492&partnerID=8YFLogxK

M3 - Article

C2 - 17725096

AN - SCOPUS:34347406492

VL - 26

SP - 175

EP - 184

JO - Journal of Experimental and Clinical Cancer Research

JF - Journal of Experimental and Clinical Cancer Research

SN - 0392-9078

IS - 2

ER -